Compare OTH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTH | PLRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.8M | 81.1M |
| IPO Year | N/A | 2020 |
| Metric | OTH | PLRX |
|---|---|---|
| Price | $3.05 | $1.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 121.5K | ★ 485.4K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $600.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $1.09 |
| 52 Week High | $3.84 | $1.95 |
| Indicator | OTH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 49.69 |
| Support Level | $3.01 | $1.12 |
| Resistance Level | $3.45 | $1.39 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 64.02 | 62.50 |
Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Dealerships and Financial Services. Dealerships segment consists of Specializing in the buying, selling, and wholesaling of yachts and boats. Having a boat dealership created to run Yellow Fin sales in Miami. Financial Services segment consists of a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages. The Dealerships segment generates maximum revenue. The services of the company includes: Sell Your Boat, Brokerage, Marine Financing, Get Pre-Qualified, Warranty & Extended Coverage, and Wholesale.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.